Stella Pharma (4888) · FactRestated
External Recognition and Selection for Efforts to Commercialize BNCT
First written in FY2024-Q2. 1 of 2 entries say "Restated". Latest entry: FY2024-Q3.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
External recognition of BNCT commercialisation and selection as an APAC companyA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2024-Q3RestatedAnnual report
「In Life Sciences Review, a business magazine providing cutting-edge information in the life sciences field, our efforts to date to commercialize BNCT were recognized, and we were selected for the magazine’s Top 10 Therapeutics Companies in APAC 2023.」
Our efforts toward commercializing BNCT were recognized by Life Sciences Review, and our selection for its Top 10 Therapeutics Companies in APAC 2023 continues to be reported. - FY2024-Q2First statedAnnual report
「In Life Sciences Review, a business magazine providing cutting-edge information in the life sciences field, our efforts to date to commercialize BNCT were also recognized, and we were selected for the magazine’s Top 10 Therapeutics Companies in APAC 2023.」
Our efforts to date toward commercializing BNCT were recognized by Life Sciences Review, and we were selected for its Top 10 Therapeutics Companies in APAC 2023.